![Jesal Shah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jesal Shah
Direttore/Membro del Consiglio presso RIGImmune, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Raj Kumar Shriram Baheti | M | 64 |
Aleor Dermaceuticals Ltd.
![]() Aleor Dermaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aleor Dermaceuticals Ltd. is an Indian company that develops and commercializes dermatology products. The joint venture company was founded in 2016. The company is based in Vadodara, India. | - |
Thomas Smart | M | - |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
Martin Driscoll | M | 65 |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
Mitanshu Shah | M | - |
Aleor Dermaceuticals Ltd.
![]() Aleor Dermaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aleor Dermaceuticals Ltd. is an Indian company that develops and commercializes dermatology products. The joint venture company was founded in 2016. The company is based in Vadodara, India. | - |
Susan Sobolov | M | - |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
Rahul Suresh Gawande | M | 34 |
Aleor Dermaceuticals Ltd.
![]() Aleor Dermaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aleor Dermaceuticals Ltd. is an Indian company that develops and commercializes dermatology products. The joint venture company was founded in 2016. The company is based in Vadodara, India. | - |
M. S. Mohan | M | - |
Aleor Dermaceuticals Ltd.
![]() Aleor Dermaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aleor Dermaceuticals Ltd. is an Indian company that develops and commercializes dermatology products. The joint venture company was founded in 2016. The company is based in Vadodara, India. | - |
Monica Zhou | M | - |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
India | 4 | 50.00% |
Stati Uniti | 4 | 50.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Jesal Shah
- Contatti personali